Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics：牵头项目 TIDAL-01 在 1 期试验中取得进展，初步临床数据预计将于 2024 年中期发布 >TSBX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册